Heterogeneity of Vaccine-Induced Immune Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination and Safety of Second Vaccination with BNT162b2

Thromb Haemost. 2022 Feb;122(2):304-307. doi: 10.1055/a-1701-2926. Epub 2022 Jan 21.

Authors

Edelgard Lindhoff-Last¹, Linda Schoenborn², Michael Piorkowski¹, Joerg Herold³, Andreas Greinacher², Jo-Ann Sheppard⁴, Theodore E Warkentin⁴

Affiliations

¹ Cardioangiology Center Bethanien Hospital, CCB Coagulation Center and CCB Coagulation Research Center, Frankfurt, Hessen, Germany.
² Department of Immunology and Transfusion Medicine, University Hospital Greifswald, Greifswald, Germany.
³ Department of Vascular Medicine/Angiology, Städtisches Klinikum Darmstadt, Darmstadt, Germany.
⁴ Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Aged
Autoantibodies / blood
BNT162 Vaccine / administration & dosage*
Biomarkers / blood
ChAdOx1 nCoV-19 / administration & dosage
ChAdOx1 nCoV-19 / adverse effects*
Female
Humans
Immunization, Secondary*
Male
Middle Aged
Platelet Factor 4 / immunology
Purpura, Thrombotic Thrombocytopenic / chemically induced*
Purpura, Thrombotic Thrombocytopenic / diagnosis
Purpura, Thrombotic Thrombocytopenic / immunology
Purpura, Thrombotic Thrombocytopenic / therapy
Vaccination / adverse effects*

Substances

Autoantibodies
Biomarkers
PF4 protein, human
Platelet Factor 4
ChAdOx1 nCoV-19
BNT162 Vaccine